I fase III- forsøget med tidligere ubehandlede myelomatosepatienter, fik 27% af patienterne profylatisk behandling med antivirale stoffer i Vc+M+P- gruppen.
In the Phase III study in patients with previously untreated multiple myeloma, 27% of patients received prophylactic antivirals in the Vc+M+P arm.